Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wainwright

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Sep 16, 2021 11:33am

130 Views

Post# 33868512

RE:RE:RE:Wainwright

Indeed negotiations are key.

Management is more aligned with shareholders given the amalgamation.

MrMugsy wrote: True - I turn specifically to the words used.
There's more information in words than in tone.

Fact is ... we wait for October to get an idea of the direction - low dose and/or high dose pathways.

Getting back to negotiations is what should be top of mind.